Citadel Advisors
PASG icon

Citadel Advisors’s Passage Bio PASG Stock Holding History

Citadel Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-625
Closed -$5K – 13740
2025
Q2 		$5K Buy
+625
New +$4.57K ﹤0.01% 12232
2024
Q4 		– Sell
-385
Closed -$5.39K – 15140
2024
Q3 		$5.39K Sell
385
-30
-7% -$478 ﹤0.01% 13496
2024
Q2 		$6.59K Sell
415
-600
-59% -$14.7K ﹤0.01% 13321
2024
Q1 		$27.4K Buy
1,015
+935
+1,169% +$22.5K ﹤0.01% 12776
2023
Q4 		$1.62K Sell
80
-250
-76% -$3.45K ﹤0.01% 13803
2023
Q3 		$4.34K Buy
330
+245
+288% +$4.02K ﹤0.01% 13494
2023
Q2 		$1.6K Sell
85
-15
-15% -$297 ﹤0.01% 13898
2023
Q1 		$1.92K Sell
100
-825
-89% -$22.4K ﹤0.01% 14233
2022
Q4 		$25.5K Sell
925
-1,495
-62% -$37.7K ﹤0.01% 12922
2022
Q3 		$61K Buy
+2,420
New +$95.4K ﹤0.01% 11490
2022
Q2 		– Sell
-555
Closed -$34K – 13777
2022
Q1 		$34K Buy
+555
New +$45.7K ﹤0.01% 13037

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's PASG Position: Q1 2026 in Review

Citadel Advisors sold out of Passage Bio (PASG) in Q1 2026, closing a stake of 17,660 shares — an estimated $208K sold.

Citadel Advisors first reported a position in PASG in Q1 2020 and held it in 21 quarters. The position peaked at $11.8M in Q1 2021. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Citadel Advisors reported no remaining Passage Bio position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 17,660 Passage Bio shares in Q1 2026, an estimated $208K.
  • Citadel Advisors first reported a position in Passage Bio in Q1 2020 and held it in 21 quarters.
  • Citadel Advisors's Passage Bio position peaked at $11.8M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.